Moderna, INC Form 4 insider transactions

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on April 3, 2024, under a pre-arranged trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on March 27, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on March 20, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Moderna's President, Stephen Hoge, sold 15,000 shares of common stock at a price of $103.17 per share on March 15, 2024, according to a Form 4 filing with the SEC.

Noubar Afeyan, a director at Moderna, sold shares of the company's common stock on March 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Legal Officer of Moderna, Shannon Thyme Klinger, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Chief Legal Officer Shannon Thyme Klinger reports the acquisition and disposal of Moderna (MRNA) stock, including transactions related to restricted stock units and tax obligations.

Moderna's President, Stephen Hoge, reported the acquisition and disposal of company stock, including transactions related to restricted stock units and tax obligations.

Chief Financial Officer of Moderna, James Mock, reports the acquisition and disposal of company stock and restricted stock units.

Shannon Thyme Klinger, Moderna's Chief Legal Officer, reported the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Moderna's President, Stephen Hoge, reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Moderna's Chief Financial Officer, James M. Mock, reported the acquisition of stock options and restricted stock units in a recent SEC filing.

Moderna's Chief Legal Officer, Shannon Thyme Klinger, reports the acquisition of stock options and restricted stock units.

Moderna's President, Stephen Hoge, reports the acquisition of stock options and restricted stock units (RSUs) in a recent SEC Form 4 filing.

Moderna's CEO, Stephane Bancel, reported the acquisition of stock options and changes in his beneficial ownership of Moderna shares through direct and indirect holdings.